Introduction
Neonatal diabetes mellitus (NDM) is defined as diabetes diagnosed within the first 6 months of life. This condition can either be permanent, requiring lifelong insulin therapy, or transient, where the condition can remit during infancy but relapse later in life. Transient and permanent NDM (TNDM and PNDM) are rare conditions with an estimated incidence of 1 in 260 000 to 500 000 live births. [1] [2] [3] PNDM is less common than the transient form, and in these patients insulin dependence is lifelong.
Here, we report on a patient with a novel missense mutation, p.P1199L, in the ABCC8 gene that encodes the sulfonylurea receptor 1 subunit of the pancreatic ATP-sensitive potassium (K-ATP) channel. The patient, who had PNDM accompanied by diabetic ketoacidosis (DKA), was admitted to the neonatal intensive care unit and was successfully transitioned from insulin to sulfonylurea therapy following the genetic diagnosis.
Case A 1-month-old girl was referred to the neonatal intensive care unit, with the complaints of tachpynea, respiratory distress, lethargy and poor feeding. The patient was born to a 34-year-old mother whose pregnancy was uneventful. A full-term female neonate weighting 3520 g (50 percentile) with a length of 52 cm (75 percentile) was delivered via elective cesarean section. The physical examination was normal and the newborn did not have any dysmorphic abnormalities at birth. Breastfeeding was started shortly after birth. She was the second child of unrelated parents. There was no family history of diabetes or autoimmune diseases. On physical examination, the infant was irritable, drowsy, dehydrated, tachypneic (72 breaths per min) and tachycardic (182 beats per min). Her body temperature was 37. , and base deficit À25.1. Urinalysis showed specific gravity 1.030, glucose 4 þ and ketones 3 þ . Serum insulin level was 0.2 mU ml À1 and C-peptide (0.04 ng ml À1 (0.3 to 1.37)) was low, while blood sugar level was 432 mg dl
À1
. The glycosylated hemoglobin level (high-pressure liquid chromatography method, HPLC) was 7.23%. Anti-insulin, anti-islet cell and anti-glutamic acid decarboxylase antibodies were found to be negative. Thyroid function tests (TSH: 2.43 mU ml À1 , fT4: 0.98 ng dl
) were within normal ranges. Tandem mass spectrometry and serum organic acids were normal. There was no clinical evidence of pancreatic exocrine insufficiency and abdominal ultrasound showed the presence of a normal-sized pancreas. Cranial magnetic resonance imaging was normal. Echocardiography revealed no abnormality. The parents' fasting blood glucose levels were normal.
A diagnosis of DKA was made and treatment was started with intravenous insulin (0.05 IU kg À1 h À1 for 2 h and 0.1 IU kg À1 h thereafter) and a rehydration solution. Insulin and glucose concentrations were subsequently adjusted according to the rate of glucose fall, and no complications were observed. Hyperglycemia and ketoacidosis resolved by the 24th hour of treatment. Breastfeeding was resumed with feedings at 3-h intervals. She was discharged 3 weeks after admission with a regimen of neutral protamine Hagendorn and regular insulin injections twice a day (0.9 U kg À1 per day). Molecular genetic analysis revealed the patient was heterozygous for a novel missense mutation, p.P1199L (c.3596C>T), in the ABCC8 gene, which encodes the sulfonylurea receptor 1. Her father and mother did not carry the mutation. The genetic analysis was performed at the Peninsula Medical School, University of Exeter, UK as previously described. 4 During the follow-up, insulin dose was decreased but serum glucose level increased again, due to increment in blood glucose levels to 150 to 450 mg dl À1 , suggesting a diagnosis of PNDM. Based on this finding, we attempted to convert her treatment from insulin to glibenclamide at the same dose (as a tablet at 5 mg dissolved in 5 ml water) as in literature cases and proceeded as per the established recommendations of Dr Andrew Hattersley (published at http://www.diabetesgenes.org). [5] [6] [7] The patient was 2 months old at the start of this transition. The patient was treated with oral glibenclamide 0.2 mg kg À1 per day with 0.1 mg kg À1 prebreakfast (0800 h) and 0.1 mg kg À1 pre-evening meal (1800 h). Dosage was increased over the next 7 days to 0.4 mg kg À1 per day, while regular insulin was concomitantly tapered off glibenclamide. Her blood sugar was regulated with that dosage. Her hyperglycemia resolved completely after her glibenclamide dose was further increased to 0.4 mg kg À1 per day, divided two times daily, and she no longer required doses of regular insulin. Three months after starting glibenclamide, the patient remained asymptomatic; her serum C-peptide level increased to 1.37 ng ml À1 (1.1 to 4.4) and HbA1c level normalized (5.8%). Only with glibenclamide treatment her insulin level was 4.36 U l À1 ; meanwhile, her blood sugar was 105 mg dl À1 , which may be accepted in the normal range. Her glibenclamide requirement slowly decreased (due to weight gain) and stabilized at 0.25 mg kg À1 per day and her blood sugar levels reached an average of around 120 mg dl À1 . She was found to be gaining weight (6.9 kg at the 25th percentile) and showing normal neurodevelopmental progress. Currently, the patient is 5 months old and is on two doses of glibenclamide (0.2 mg kg À1 per day).
Discussion
Neonatal/infancy-onset diabetes mellitus (NDM) is a monogenic form of diabetes. In patients with TNDM, remission of hyperglycemia usually occurs within 3 to 6 months from diagnosis. Permanent NDM is less common than TNDM and never goes into remission. It accounts for approximately 40 to 50% of NDM cases. 8 Several reviews were reported that ketonuria is usually mild or absent; however, DKA may develop when the diagnosis is delayed in NDM. 8, 9 Our patient was misdiagnosed as having pneumonia in another hospital. We think that the cause of DKA in our case was due to delayed diagnosis or late admission to the emergency unit. Also, NDM associated with DKA may mimic sepsis or pneumonia and should be kept in mind in all newborns who present with tachypnea, respiratory distress, dehydration and weight loss.
Permanent NDM is associated with defects in genes that have major roles in pancreatic beta cell development and function. Besides the imprinting abnormalities at chromosome 6q24 first described for TNDM mutations in the genes, KCNJ11 and ABCC8 that encode the subunits Kir6.2 and sulfonylurea receptor 1 of KATP channel are a common cause of both transient and permanent forms of NDM. Mutations in the glucokinase (GCK) and Insulin (INS) genes have also been reported in patients with PNDM. Moreover, individuals with some exceedingly rare forms of syndromic PNDM may bear recessive mutations in several genes, including PDX1, EIF2AK3, PTF1A, GLIS3, RFX6, SLC19A2, GATA6, NUEROG3, NEUROD1 or FOXP3.
3,10 Russo et al. 10 reported that a molecular genetic diagnosis can be reached in B75% of patients with diabetes onset at p6 months of age when KCNJ11, INS and ABCC8 genes are sequenced in populations with a low consanguinity rate. Flanagan et al. 4 reported that a genetic diagnosis was possible for up to 97% of patients with TNDM in a cohort collected across four continents following a request of the International Society of Paediatric and Adolescent Diabetes. The majority of these patients (71%) had chromosome 6q24 imprinting abnormalities, while 26% of cases had a KATP channel mutation.
Heterozygous gain-of-function mutations in the KCNJ11 and ABCC8 genes are the most common cause of NDM, which for the vast majority of cases can be treated with oral sulfonylureas.
3,5,10 Our patient was heterozygous for a missense mutation, p.P1199L, in ABCC8, allowing us to convert her treatment from insulin to glibenclamide, which resulted in an improvement in glycemic control.
In conclusion, this is one of the youngest reported patients to commence oral glibenclamide therapy for treatment of NDM resulting from a novel mutation in the ABCC8 gene. This case illustrates safe and effective initiation of glibenclamide in PNDM due to mutations in the K þ ATP channel genes. These patients can be successfully treated with oral sulfonylurea instead of subcutaneous insulin therapy. Further genetic investigation should focus on assessment in NDM for therapy options.
